Literature DB >> 15252265

Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study).

C Warren Olanow1, Philippe Damier, Christopher G Goetz, Thomas Mueller, John Nutt, Olivier Rascol, Alexandru Serbanescu, Frieda Deckers, Hermann Russ.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15252265     DOI： 10.1097/00002826-200403000-00003

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN： 0362-5664            Impact factor:   1.592


× No keyword cloud information.
  43 in total

1.  Possible role for chlorpheniramine in the treatment of L-DOPA induced dyskinesia in Parkinson's disease.

Authors:  Petros N Karamanakos; Periklis Pappas; Marios Marselos
Journal:  Pharm World Sci       Date:  2007-06-28

2.  Changes in sleep electroencephalogram and nocturnal hormone secretion after administration of the antidyskinetic agent sarizotan in healthy young male volunteers.

Authors:  Heike E Kuenzel; Axel Steiger; Katja Held; Irina A Antonijevic; Ralf-Michael Frieboes; Harald Murck
Journal:  Psychopharmacology (Berl)       Date:  2005-02-17       Impact factor: 4.530

Review 3.  Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.

Authors:  Mahmoud M Iravani; Peter Jenner
Journal:  J Neural Transm (Vienna)       Date:  2011-09-01       Impact factor: 3.575

Review 4.  Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.

Authors:  Eva Schaeffer; Andrea Pilotto; Daniela Berg
Journal:  CNS Drugs       Date:  2014-12       Impact factor: 5.749

Review 5.  The serotonergic system in L-DOPA-induced dyskinesia: pre-clinical evidence and clinical perspective.

Authors:  Manolo Carta; Anders Björklund
Journal:  J Neural Transm (Vienna)       Date:  2018-02-26       Impact factor: 3.575

6.  The effects of BMY-14802 against L-DOPA- and dopamine agonist-induced dyskinesia in the hemiparkinsonian rat.

Authors:  Nirmal Bhide; David Lindenbach; Margaret A Surrena; Adam A Goldenberg; Christopher Bishop; S Paul Berger; Melanie A Paquette
Journal:  Psychopharmacology (Berl)       Date:  2013-02-07       Impact factor: 4.530

Review 7.  Role of adenosine A2A receptors in motor control: relevance to Parkinson's disease and dyskinesia.

Authors:  Annalisa Pinna; Marcello Serra; Micaela Morelli; Nicola Simola
Journal:  J Neural Transm (Vienna)       Date:  2018-02-02       Impact factor: 3.575

8.  Effects of 5-HT1A receptor stimulation on D1 receptor agonist-induced striatonigral activity and dyskinesia in hemiparkinsonian rats.

Authors:  Kristin B Dupre; Corinne Y Ostock; Jessica A George; Karen L Eskow Jaunarajs; Cara M Hueston; Christopher Bishop
Journal:  ACS Chem Neurosci       Date:  2013-04-01       Impact factor: 4.418

9.  The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanism.

Authors:  Melanie A Paquette; Katherine Foley; Elizabeth G Brudney; Charles K Meshul; Steven W Johnson; S Paul Berger
Journal:  Psychopharmacology (Berl)       Date:  2009-03-13       Impact factor: 4.530

10.  Assessment of symptomatic and neuroprotective efficacy of Mucuna pruriens seed extract in rodent model of Parkinson's disease.

Authors:  Sanjay Kasture; Silvia Pontis; Annalisa Pinna; Nicoletta Schintu; Liliana Spina; Rosanna Longoni; Nicola Simola; Mauro Ballero; Micaela Morelli
Journal:  Neurotox Res       Date:  2009-02-20       Impact factor: 3.911
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.